News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Bio-Rad Laboratories, Inc. (BIO) and Myriad Genetics, Inc. (MYGN) Partner to Commercialize Multiplex Biomarker Kits for Life Science Research


7/25/2012 8:57:12 AM

HERCULES, CA and AUSTIN, TX--(Marketwire - July 24, 2012) - Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.B), a multinational manufacturer and distributor of life science research and clinical diagnostic products, and Myriad RBM, Inc., a wholly owned subsidiary of Myriad Genetics Inc. (NASDAQ: MYGN), and a leading multiplex biomarker testing company, today announced that they have partnered to develop and distribute high-quality immunoassay kits. Under the terms of the agreement, Myriad RBM grants Bio-Rad exclusive distribution rights, for research purposes, to the largest catalog of quantitative multiplexed immunoassays currently available to run on the Bio-Plex® 200, Bio-Plex® 3D, and Bio-Plex® MAGPIX™ instruments.

Myriad RBM's assays address researchers' needs for multiplex testing of samples with very low volumes when studying toxicology, oncology, immunology, and cardiovascular and other diseases. The new assays expand Bio-Rad's current suite of assays.

"Together we are able to provide hundreds of new biomarkers for both human and non-human panels to our Bio-Plex multiplex immunoassay system menu," said Brad Crutchfield, Bio-Rad Vice President and Group Manager, Life Science Group. "Moving forward, Myriad RBM and Bio-Rad will collaborate to design new products to meet the evolving requirements of our customers."

"This agreement combines Myriad RBM's industry-leading menu of multiplexed immunoassays with Bio-Rad's unrivaled global commercial distribution capabilities," said Craig Benson, President of Myriad RBM. "Our partnership with Bio-Rad will help researchers and clinicians on the front lines of medicine to develop biomarker profiles that may predict, detect, or monitor disease progression in an effort to optimize treatment and improve patient care."

For further information on Bio-Plex assays, please visit www.bio-rad.com/ad/plexibility

About Myriad RBM
Myriad RBM's biomarker discovery platform provides clinical researchers, physicians, and healthcare providers with reproducible quantitative multiplexed data for hundreds of proteins to advance drug development and patient care. The company's proprietary Multi Analyte Profiling (MAP) technology offers preclinical and clinical researchers broad, cost-effective analyses of multiple proteins from a single small sample volume. Myriad RBM's MAP technology also supports the development of companion diagnostics in areas of unmet medical need within the fields of neurology, psychiatry, nephrology, endocrinology, oncology, and immunology. Myriad RBM is a wholly owned subsidiary of Myriad Genetics (MYGN). More information about Myriad RBM is available at www.myriadrbm.com.

About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.B) has remained at the center of scientific discovery for more than 50 years, manufacturing and distributing a broad range of products for the life science research and clinical diagnostic markets. The
company is renowned worldwide among hospitals, universities, major research institutions, as well as biotechnology and pharmaceutical companies for its commitment to quality and customer service. Founded in 1952, Bio-Rad is headquartered in Hercules, California, and serves more than 100,000 research and industry customers worldwide through its global network of operations. The company employs over 7,100 people globally and had revenues exceeding $2 billion in 2011. For more information, visit www.bio-rad.com.

This release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements generally can be identified by the use of forward-looking terminology such as, "believe," "expect," "may," "will," "intend," "estimate," "continue," or similar expressions or the negative of those terms or expressions. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. For further information regarding the Company's risks and uncertainties, please refer to the "Risk Factors" in the Company's public reports filed with the Securities and Exchange Commission, including the Company's most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. Bio-Rad Laboratories, Inc., disclaims any obligation to update these forward-looking statements.

For further information regarding Myriad RBM's uncertainties, please refer to the heading "Risk Factors" contained in Item 1A in Myriad Genetics' most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. All information in this press release is as of the date of the release, and Myriad undertakes no duty to update this information unless required by law.

xMAP and Luminex are trademarks of Luminex Corporation.


Press Contacts:

Bio-Rad Laboratories, Inc.
Tina Cuccia
Corporate Communications
510-724-7000
Email Contact

Myriad RBM, Inc.
Christopher Martin
Director of Communications
512-275-2623
Email Contact

Myriad Genetics
Rebecca Chambers
Director of Investor Relations and Corporate Communications
801-584-1143
Email Contact


Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES